Tuesday, Indivior Plc (NASDAQ:INDV) announced a downward revision of its profit forecast for the year while deciding to cease sales of its schizophrenia drug Perseris. The company also plans to reduce its workforce by about 130 jobs. In a business update, Indivior outlined its expectations for the second quarter and full-year 2024. Related: Addiction Treatment Company, Indivior, Reports 12% YoY Growth For First Quarter Led By Sublocade Sales. The company adjusted its second-quarter net revenue expectations and FY 2024 guidance, citing continued adverse market conditions affecting Sublocade’s near-term growth and the initial commercial uptake of Opvee. At the mid-point, Indivior anticipates a 25% year-over-year net revenue growth for Sublocade and a 12% year-over-year increase in adjusted operating income for fiscal 2024. The company forecasts fiscal 2024 revenue of $1.15 billion-$1.215 billion, versus prior guidance of $1.24 billion -$1.33 billion and a consensus of ...